Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
14 Apr 2022
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumo...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022
METNET: A phase II trial of metformin in patients with well differentiated neuro...
Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours ( Dr João Glasberg - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil )
31 Mar 2022
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari
EGFR testing: Best practice for NSCLC patients with exon 20 insertions ( Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari )
30 Mar 2022
ASCO GU 2022: Latest in mHSPC
Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith
ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )
8 Mar 2022
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE
Dr Neal Shore and Prof Kim Chi
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )
4 Mar 2022
SG in combination with pembro in patients with mUC who progressed after platinum...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
28 Feb 2022
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion
Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion ( Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA )
28 Feb 2022
Latest developments in mHSPC
Prof Kurt Miller and Prof Laura-Maria Krabbe
Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )
25 Feb 2022
ASCO GU 2022: The latest in CRPC, including PARP combo data
Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Mers...
ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )
25 Feb 2022
Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in a...
Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spai...
Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
21 Feb 2022